Factors Associated with Medicine Timing Effects: A Meta-analysis
================================================================

* Marc D. Ruben
* Lauren J. Francey
* Gang Wu
* David F. Smith
* Garret A. FitzGerald
* Jacob J. Hughey
* John B. Hogenesch

## Abstract

**Importance** Clinical evidence suggests that the time of day of treatment can affect outcomes in many different diseases, but this information is dispersed, imprecise, and heterogeneous. Consequently, practice guidelines and clinical care recommendations seldom specify intervention time.

**Objective** To understand the sources of variability and summarize clinical findings on the time of day effects of medicine.

**Data Sources** A systematic search of Pubmed, Google Scholar, and [ClinicalTrials.gov](http://ClinicalTrials.gov) for “chronotherapy” OR “time of administration”.

**Study Selection** Any clinical study since 2000, randomized or observational, that compared the effects of treatment at different times of day. We included pharmacologic or surgical interventions having at least one continuous outcome.

**Data Extraction and Synthesis** For selected studies, we extracted the mean and variance of each time-of-day treatment group. From these, we computed the standardized mean difference (SMD) as the measure of timing effect. Where a study reported multiple outcomes, we selected a single outcome based on a defined order of priority.

**Main Outcomes and Measures** We estimated overall pooled effect size and heterogeneity by a random effects model, followed by outlier detection and subgroup analyses to evaluate how study factors, including drug, design, outcome, and source, associate with timing effect.

**Results** 78 studies met the inclusion criteria, comprising 48 distinct interventions over many therapeutic areas. We found an overall effect of time on clinical outcomes but with substantial heterogeneity between studies. Predicted effects range from none to large depending on the study context. Study size, registration status, and source are associated with the magnitude of effect. Larger trials and those that were pre-registered have markedly smaller effects, suggesting that the published record overstates the effects of the timing of medicine on clinical outcomes. In particular, the notion that antihypertensives are more effective if taken at bedtime draws disproportionately from one source in the field, which consistently detects larger effects than the community average. Lastly, among the most highly studied drug timing relationships, aspirin’s anti-clotting effect stands out, consistently favoring evening over morning dosing.

**Conclusions and Relevance** While accounts of drug timing effects have focused on *yes/no*, appreciating the range of probable effects may help clarify where ‘circadian medicine’ meets the threshold for clinical benefit.

## Introduction

Half of human genes and the physiology they control are expressed with a 24 h rhythm with implications for medicine 1,2. Treatment time effects can in theory arise from circadian influences on pharmacokinetics, pharmacodynamics, or underlying physiology. Indeed, dozens of clinical trials suggest that time of dosing can affect responses in cancer, heart, lung, and other diseases. Even vaccines may be influenced by the timing of their administration 3,4. Yet, outside of sleep medicine, time of day is rarely considered in medical practice. The most recent WHO Model List of Essential Medicines makes no mention of dosing time. In view of notable advances in circadian biology research, why are there so few examples of clinical use?

Dosing time has been most studied in hypertension, and randomized trials seem to converge on a few fundamentals 5–7. For example, multiple randomized trials show that short-acting antihypertensives taken at bedtime better restore the normal overnight drop in blood pressure compared to morning dosing 6. But even here there is uncertainty. Trials differ by drug, design, and endpoint, and not all findings point in the same direction. Of the dozens of antihypertensive medications, none have garnered an FDA time-of-day directive, and the importance of dosing time is disputed 8–12. In fact, we have only a superficial understanding of how much treatment time affects cardiac outcomes; this question applies to all indications. A history of trials report treatment time differences, but information is heterogeneous and imprecise. There is a need to synthesize the evidence.

To understand the sources of variability and more adequately summarize clinical findings on the time-of-day uses of medicine, we analyzed 78 studies that compared treatment at different times of day. This comprised 48 distinct interventions over many therapeutic areas. To our knowledge, this is the largest such analysis to date.

## Methods

### Study Identification

We conducted a systematic search of PubMed, [ClinicalTrials.gov](http://ClinicalTrials.gov), and Google Scholar for clinical studies that compared the effects of treatment administered at different times of day in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. The first search was performed in March 2020. We used the search terms “chronotherapy” or “time of administration” and included only articles in English.

After title and abstract screening, the full texts of potentially relevant studies were reviewed and selected if they evaluated the effects of the same treatment given at different times of day. We allowed any pharmacologic or surgical intervention as long as the study tested at least one continuous outcome measure. Because the aim of our study was a broad evaluation of medicine timing effects, we allowed any study design––randomized or observational, and any disease context, study population, and outcome/endpoint––as long as the effect mean and variance of each time-of-day group were available. The only exception to this were studies addressing sleep disorders, which we excluded.

We screened the hits from the initial search for relevant references. We performed a final search of the same three databases in June 2021 (Fig. 1 Supplement). Our final selection includes studies meeting the above criteria published since January 1st 2000.

### Data Extraction and Methodological Quality Assessment

This study was not submitted for institutional review board approval because it did not involve individual patient information and all data extraction was from publicly available sources. We collected study characteristics: drug ingredient, drug class, drug half-life, study design, registration status, treatment setting, patient demographics, investigator source, and primary and secondary outcomes. For study outcomes, we extracted the size, mean, and variance of each time-of-day treatment group.

While we did not grade the quality of each study a priori, we collected study characteristics used by established methods of grading 13. We sought to understand sources of heterogeneity in the body of literature and our analyses consider several commonly used proxies for quality.

### Statistical Analysis

We computed Cohen’s d standardized mean difference (SMD) for each continuous outcome, from each study 14. Specifically, we subtracted the mean post-evening-treatment outcome from the mean post-morning-treatment outcome and divided the result by the pooled standard deviation for both groups (Eq. 1 and Eq. 2). Where more than two times of day were tested, we computed the SMD between the two groups with the largest raw mean difference. ![Formula][1]</img>  ![Formula][2]</img>  n1, s1: sample size and standard deviation of evening group

n2, s2: sample size and standard deviation of morning group

To correct for small-sample bias in Cohen’s SMD, we converted Cohen’s SMD to Hedge’s SMD 15 using the R package ‘esc’ 16. Standard error (SEM) of SMD was computed according to Eq. 3 17. Datafile 1 in the supplement contains the fully curated and coded dataset. ![Formula][3]</img>  

We prioritized end-of-study means as opposed to baseline subtracted, ie. change score, means. In rare cases where means were baseline-covariate-adjusted, we prioritized these, as reported in Data file 1 in the supplement. In cases where within-group variances were expressed as standard error of the mean (SEM) or 95% confidence intervals, we computed SD according to methods described in the Cochrane Handbook for Systematic Reviews of Interventions 18. If only median and interquartile range were reported, mean and SD were approximated 19,20.

Where a study reported multiple continuous outcomes, we selected a single outcome based on the following order of priority: (i) significant effect (p < 0.05) *and* a designated primary endpoint, (ii) designated primary endpoint, (iii) significant effect, and lastly (iv) none of the above. If multiple outcomes remained, we selected the one with the largest SMD to include in the meta-analysis.

In a small number of cases, we excluded certain outcomes from eligibility (Data file 1 in the supplement). For example, whereas awake/asleep ambulatory blood pressure are well accepted clinical endpoints in a study of hypertension, mean blood pressure over an arbitrarily defined window, eg. 11AM to 3PM, is not.

In our primary analysis, we estimated the overall SMD across studies by pooling the individual study SMDs using a random-effects model with a DerSimonian-Laird estimator 21 via the R package ‘meta’ 22. To identify potential sources of heterogeneity between studies, we recalculated the meta-analysis results N times, each time leaving out one study, and then prespecified subgroup analyses were performed using a mixed-effects model via the R package ‘dmetar’ 23. The mixed-effects model estimates the variability within subgroups as a random effect and the variability between subgroups as a fixed effect. A p-value for difference between groups was calculated via Q-test. Subgroups evaluated include study design, registration status, source, and drug kinetics. Drug half-lives were extracted from DrugBank 5.0 24, FDA-label, or research publication. We evaluated for small-study bias via funnel plot 25,26.

Our study includes two secondary analyses. The first compares *raw* mean differences among a set of blood pressure studies with outcomes on the same unit scale, by drug type and kinetics, patient demographics, and the study source. The second analysis evaluated the reproducibility of interventions tested in more than one study.

## Results

Our search revealed 172 potentially relevant reports, of which 78 fulfilled our eligibility criteria (Fig. 1 Supplement). The 78 studies encompass 48 distinct treatments tested at different times of day in multiple disease settings (Figure 1A, Data file 1 Supplement, Methods). Most studies tested only two time points, typically morning and evening.

![Fig. 1.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2021/10/26/2021.10.24.21265348/F1.medium.gif)

[Fig. 1.](http://medrxiv.org/content/early/2021/10/26/2021.10.24.21265348/F1)

Fig. 1. Effects of intervention time in clinical studies.
(**A**) 78 studies since 2000 (black triangles) that tested the impact of time of day on treatment outcomes. Data file 1 in the Supplement holds the full curated dataset. (**B**) Standardized mean difference (SMD) grouped by the type of outcome measure, where ![Graphic][4]</img> divided by the pooled standard deviation. *Filled circles*: outcomes that were reported in the original research as significant at p < 0.05 by null hypothesis testing. SMD values were capped at 1.5 for visualization, impacting two blood pressure studies with SMDs of 6.7 and 2.9, both set to 1.5 in this plot. All raw data is available in Data file 1 in the Supplement. (**C**) Absolute SMD with 95% confidence interval. *Blue diamond*: pooled effect under a random effects model. *Red bar*: Prediction interval within which future studies can be expected to fall. *Grey vertical line:* zero timing effect. *Inset table*: between-study heterogeneity. Note: We removed one extreme outlier study for visualization purposes only, Farah et al 2013, with SMD = ∼7.

### Standardized effects of time across interventions

We hoped to gain a sense of which interventions were most susceptible to time of day effects. We computed the standardized mean difference (SMD) 14,17 for each study (Fig. 1B). SMD provides a measure of effect size that is relative to variance within the study. Specifically, we subtract the mean of one time-of-day group from the other and divide the result by the pooled standard deviation (SD) (Methods). Effect sizes are given as a fraction of the standard deviation. This measure is independent of the units or scale in the original study and allows for comparisons across studies. A study with SMD = 0.5 indicates the two groups differ by 0.5 SD, SMD = 1 indicates the two groups differ by 1 SD, and so on. Where a study reported multiple outcomes, we selected a single outcome based on an order of priority described in Methods.

SMDs range from −0.16 to 6.7 (Fig. 1B), with positive values indicating that evening dosing was favorable to morning dosing, and vice versa. Evening dosing was favorable in most studies (68%). SMD alone, however, does not indicate sampling error, as studies differ in precision. To estimate the overall effect of time, we pooled all studies together under a random effects model which weights studies based on their estimated precision (Fig. 1C). The pooled estimate is therefore a measure of the mean of a distribution of true effects 17,27. The estimated absolute SMD of 0.41 (95%CI: 0.34 - 0.49, p < 0.0001) indicates an overall positive effect of time. However, model indicators 28 suggest substantial between-study heterogeneity (Fig. 1C; I2 = 82%, ie., the percent of variability not caused by sampling error). The wide prediction interval 29 from −0.12 to 0.94 means that the pooled estimate of 0.41 is unlikely to be robust in every context. We expect some future studies will find little or no timing effect, whereas others will find large effects. This led us to ask which studies were more or less influential in this prediction.

### Leave-one-out analysis identifies an investigator source of heterogeneity

To identify sources of heterogeneity between studies we recalculated the meta-analysis results N times, each time leaving out one study. This allows us to detect the contribution of each study to the overall pooled effect (Fig. 2A, left). Specifically, the ‘difference in fit(s)’ (DFFITS) metric 30 quantifies how much and in which direction the pooled effect changes when a study is omitted. Among the 12 most effect-lowering studies, nine of them relate to blood pressure, seven of which draw from sites in Northwest Spain (N.W. Spain) involving the same investigator (Fig. 2A, middle). This source is responsible for 13 of the 39 blood pressure studies in this meta-analysis, with the other 26 studies spread across different investigative groups and locations (Data file 1 Supplement). Using a mixed-model approach that pools the effect of subgroups and compares between them 31, the pooled effect from N.W. Spain is 0.80 (95%CI: 0.52 - 1.1) compared to 0.33 (95%CI: 0.24 - 0.41) for all others (p < 0.005) (Fig. 2B). We explore this further in a later section.

![Fig. 2.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2021/10/26/2021.10.24.21265348/F2.medium.gif)

[Fig. 2.](http://medrxiv.org/content/early/2021/10/26/2021.10.24.21265348/F2)

Fig. 2. Study source and pre-registration condition effect size.
(**A**) Size and direction of the change in the pooled effect when each study is omitted. DFFITS on the y-axis is expressed in standard deviations; larger values indicate decreased pooled effect when the study is omitted, and vice versa. Top 10 increases and decreases labeled. DFFITS values were capped at 0.35 for visualization, impacting two blood pressure studies with values of 6.7 and 2.9. (**B**) Subgroup analysis of Northwest Spain (N.W. Spain) vs.other studies. *Blue line:* pooled effect of all studies. (**C**) Subgroup analysis of pre-registered versus non-pre-registered for all studies (left panel) or omitting N.W. Spain (right panel). *Blue line:* pooled effect for all studies. (**D**) Study precision (SEMSMD) versus effect (SMD). *Blue vertical line:* pooled effect. *Blue diagonal lines:* pseudo 95th percentile confidence intervals around the pooled average as precision decreases from zero. P value from Egger’s test for asymmetry of the funnel plot. Absolute SMD values were capped at 2.5 for visualization only, impacting two blood pressure studies, SMD = 6.7 and 2.9, both set to 2.5 in this plot. *Drug class abbreviations:* ARB: angiotensin receptor blocker, CCB: Ca2+ channel blocker, nAChRi: anticholinergic, NSAID: non-steroidal anti-inflammatory, mixed AH: combination of antihypertensives, ACEi: angiotensin converting enzyme inhibitor; A2-agonist: alpha-2 adrenergic receptor agonist, CORT: corticosteroid, antihistH1: antihistamine, GlucagonR-i: glucagon-like peptide-1 receptor agonist, VKA: vitamin K antagonist.

### Timing effects are associated with registration status

We evaluated whether there are other study contexts where effects are lower or higher. Using a mixed model approach as above, we tested the impact of study pre-registration and design.

Clinical study registration provides transparency and discourages publication bias. Because only 34 of 78 studies in this analysis were prospectively registered on [ClinicalTrials.gov](http://ClinicalTrials.gov) or an international equivalent, we speculated that the overall evidence base may be distorted. The idea is that without a public record, negative or null trial results may be less likely to be published 32,33. Indeed, the pooled effect of pre-registered studies is 0.26 (95%CI: 0.19 - 0.34) compared to 0.57 (95%CI: 0.43 - 0.72) for non-registered studies (p < 0.001) (Fig. 2C). The pooled effect of pre-registered studies becomes even smaller (0.16, 95%CI: 0.09 - 0.22) if we omit all studies from N.W. Spain, several of which were pre-registered.

We found no evidence of association between study design and effect (Fig. 1A Supplement). Although parallel trials had a larger effect than crossover or retrospective designs, this difference can be explained by N.W. Spain studies, most of which were parallel designs.

### A small-study effect may indicate publication bias

There is a tendency for smaller studies in a meta-analysis to show larger effects 34,35. One possible cause is reporting bias, whereby small negative studies are less likely to be published. Funnel plots are commonly used to investigate small-study bias. The principle is that as studies increase in size and precision, their location around the pooled average effect narrows, forming a funnel. In the absence of bias, small (less precise) study effects should scatter widely, with spread narrowing for larger (more precise) studies. Our analysis detects asymmetry indicative of small-study bias (Fig. 2D). Specifically, the largest studies fall to the left of the pooled effect. This imbalance, together with the prior observation that pre-registered studies have smaller effect sizes, suggests that the published record overstates medicine timing effects.

### The evidence for medicine timing in hypertension

Half of the studies in this meta-analysis concern the timing of antihypertensives. More than one-third of these antihypertensive studies originate from N.W. Spain. Understanding *why* findings from N.W. Spain appear as outliers is important from both a research and clinical perspective.

We first evaluated whether N.W. Spain’s large effects may be due to lower study variances. SMD is scale-free and not influenced by the units of measurement. However, choices made by an investigator, such as enrolling a narrow patient population, can reduce study variance, which may cause SMD to appear larger 36,37. Therefore, we computed raw mean differences (RMD = mean mmHgmorning – mean mmHgevening) for each of the 38 studies with blood pressure outcomes on the same scale. We focused on nighttime blood pressure because of its prognostic 38–40 and circadian 41–44 relevance. Overall, RMDs suggest that evening dosing is preferable to morning dosing for lowering nighttime blood pressure (Fig. 3A). However, the median RMD from N.W. Spain (5.5 mmHg) is markedly larger than other studies (1.7 mmHg). Put another way, N.W. Spain is also an outlier by RMD, as it was by SMD. Perhaps interestingly, N.W. Spain studies do have lower variances, ie. pooled standard deviations (Methods) (Fig. 3A) on average, but this is unlikely to explain the large discrepancy in RMD.

![Fig. 3.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2021/10/26/2021.10.24.21265348/F3.medium.gif)

[Fig. 3.](http://medrxiv.org/content/early/2021/10/26/2021.10.24.21265348/F3)

Fig. 3. Factors influencing dosing time effects on nighttime blood pressure.
(**A**) 38 studies that tested the effect of morning versus evening dosing on nighttime systolic blood pressure. Effect is shown on the vertical axis as raw mean difference (RMD) where RMD = mean mmHgmorning – mean mmHgevening. Study variance is shown on the horizontal axis as pooled standard deviation (Methods). Marginal boxplots summarise how RMD and variance are distributed. (**B**) *Top row*: density plots indicate relative numbers of studies at different values of drug half life, mean patient age, and percent sex. *Orange lines*: N.W. Spain; *grey lines*: all other studies. *Bottom row*: regressing RMD onto drug half-life, mean patient age, and percent sex. Smooth lines fit by the generalized additive model y ∼ s(x, bs = “cs”, knots = 5), where y = RMD, x = covariate, cs = cubic spline basis function. Grey shading: 95% confidence intervals. Drug half-lives obtained from DrugBank 5.0, FDA-label, or research publication. For studies with drug combinations, the shortest-acting ingredient is considered.

Can differences in the types of drugs studied explain the discrepancy? N.W. Spain has larger RMDs for all six mono- or dual-therapies that were also studied by at least one outside group (Fig. 1B Supplement). Further, the distributions of study drug half-lives are virtually indistinguishable between N.W. Spain and others (Fig. 3B, top left). Therefore, differences in the nature of the drugs studied cannot explain the discrepancy.

We next evaluated patient composition. N.W. Spain consistently enrolled a larger share of younger and female patients than other studies (Fig. 3B, top middle and right panels). This difference in study makeup is dramatic, and sex-specific effects of drug timing have been observed in other contexts 45,46. However, closer inspection of the data refutes this idea, as neither sex nor age track with RMD (Fig. 3A, bottom middle and right panels). In sum, the idea that antihypertensives, even short-acting, are more effective if taken at night is only weakly supported by the broader research community.

### Aspirin’s time-dependent anti-coagulative effect stands out

This meta-analysis includes studies in many conditions other than hypertension. We evaluated if there are particular areas of medicine with orthogonal lines of support for the importance of time. There were too few studies per outcome to justify regression-based subgroup analyses, so we simply visualized effect (SMD) versus precision (SEM) for each of the 38 non-hypertension studies. With the exception of airway patency, where studies can be characterized as high precision but small effect, there are no remarkable differences between outcomes (Fig. 4A, left).

![Fig. 4.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2021/10/26/2021.10.24.21265348/F4.medium.gif)

[Fig. 4.](http://medrxiv.org/content/early/2021/10/26/2021.10.24.21265348/F4)

Fig. 4. Assessment of reproducibility.
(**A**) *Left*: absolute SMD versus precision (SEM) for all meta-analysis studies, excluding blood pressure outcomes (n = 38). *Point shape*: whether morning or evening treatment was more effective. *Right*: the five intervention::outcome pairs tested in more than one study: (i) aspirin::coagulation, (ii) levothyroxine::thyroid function, (iii) insulin glargine::glucose levels, (iv) simvastatin::lipid levels, and (v) atorvastatin::lipid levels. Pairs are encircled to highlight group coherence. (**B**) All outcomes of aspirin in coagulation for each of the five studies of aspirin in this meta-analysis (n = 10). Data presented here deviate from our meta-analysis inclusion criteria of one outcome per study (described in text, Methods). Point *shape*: study reference. *Abbreviations:* ARU: aspirin relative units from VerifyNow test.

We next assessed reproducibility, focusing on the five intervention::outcome pairs tested in more than one study: (i) aspirin::coagulation, (ii) levothyroxine::thyroid function, (iii) insulin glargine::glucose levels, (iv) simvastatin::lipid levels, and (v) atorvastatin::lipid levels (Fig. 4A, right). Simvastatin and aspirin were consistently more effective when taken in the evening, whereas insulin glargine was more effective when taken in the morning. Levothyroxine and atorvastatin were inconsistent, favoring evening dosing in some studies and morning in others.

All aspirin studies in this meta-analysis tested low 75-100 mg ‘cardiopreventive’ doses. Aspirin has well established anti-thrombotic efficacy and low-dose aspirin is standard-of-care for secondary prevention of cardiovascular disease 47, taken daily by millions of patients. The understanding that its effect is sensitive to timing is not reflected in current dosing guidelines. Given the potential clinical importance, we examined all available evidence. As a reminder, we selected only a single outcome per study to include in the meta-analysis, based on a defined order priority (Methods). However, secondary and other endpoints in a study are also informative. To scrutinize all available evidence, we compared all of the reported outcomes of aspirin in coagulation for all aspirin studies in this meta-analysis (Fig. 4B). Eight out of ten outcomes favored evening over morning dosing, across different assays of platelet inhibition.

Our prior work suggested that short-acting drugs are more likely to show timing effects 7. This assessment relied on a binary yes/no measure of effect, ie. significance p< 0.05. We re-evaluated the impact of half-life via meta-regression 22 onto SMD, and found half-life to be a surprisingly poor predictor of effect size (slope = −0.0008, p = 0.8, R2 = 0) (Fig. 2C Supplement). Of note, our prior assessment included several studies of short-acting anti-cancer agents that were not part of this study because they reported only binary outcomes.

## Discussion

Treatment time effects can in theory arise from time-of-day influences on pharmacokinetics, pharmacodynamics, or underlying physiology. As genome-wide circadian datasets grow, so have predictions of medicine timing effects. In the past five years, ∼150 reviews mentioned ‘chronotherapy’ or ‘circadian medicine’ in the title or abstract, outpacing clinical evidence.

In this meta-analysis, we estimate a summarized effect of time of 0.41 standard deviations. What does this mean? While there is no straightforward way to assign reference values, an analysis of the most common drugs versus placebo found effects from SMD=0.1 to SMD=1.4 48. In this context, timing effects from several studies were as large as many drug-versus-nothing effects. Unfortunately, the evidence for many of the interventions draws from a single trial of low precision. Which interventions are well-supported clinical opportunities that deserve focus?

Evidence from aspirin studies in this meta-analysis warrants future randomized controlled trials of aspirin timing in the prevention of cardiac events. Aspirin inhibits platelet reactivity and is widely used for cardiovascular disease prevention for this reason 49. Aspirin’s efficacy is attributed to its inhibition of cyclo-oxygenase-1 (COX-1) leading to inhibition of thromboxane A2 production by platelets 50. Interestingly, because the COX-1 inhibition is irreversible, aspirin’s therapeutic effect is traditionally thought to be sustained throughout the dosing interval once steady state is achieved. What, then, accounts for the dosing time effect on platelet reactivity observed in trials in this meta-analysis? One possibility is drug kinetics and platelet turnover. Aspirin has a short ∼1 h half-life and inhibits only the platelets present at the dosing time. New platelets are released at a rate of 10% per day 51,52 and it has been shown that the antiplatelet effect of aspirin declines during the 24 h dosing interval 53,54. Alternatively, the variable inhibition of other coagulation factors, such as prostaglandin I2, may modulate aspirin’s therapeutic platelet inhibition. Importantly, it is well established that platelet reactivity and coagulation peak in the morning 41,42. Approximately 300K recurrent cardiovascular events occur in the United States every year, with an excess of 40% during the morning hours 55. Even a small reduction in the morning peak could translate to a large decrease in recurrent events per year 56.

Studies of aspirin in platelet inhibition 57 underscore another point: the better time for treatment should be interpreted in the context of what was measured. For example, whereas morning dosing of proton pump inhibitors (PPIs) was more effective for *activity*-induced gastroesophageal reflux, evening dosing was more effective for *nocturnal* reflux 58. Constriction of the airway and pain also tend to peak at night. In this sense, optimal timing may be a matter of aligning drug exposure with a 24 h rhythmic symptom.

No area of drug timing has more published studies and debate than hypertension. Daily rhythms in blood pressure are well-documented. Disruption of these rhythms, in particular the loss of normal nighttime ‘dipping’, is associated with increased cardiovascular risk 38–40. Evidence that bedtime ingestion of antihypertensives is more effective for controlling nighttime blood pressure is therefore of wide interest. And interestingly, the greatest effects are seen with aspirin, findings that have been reproduced in mice 59. However, the clinical evidence draws largely from one source with effect sizes that are difficult to reconcile with the broader field. While confusing, we expect that continued advances in understanding the time-of-day-dependent mechanisms of cardiovascular function will clarify the role of time in treatment of heart disease.

## Limitations

SMD is an imperfect metric. Although insensitive to measurement units and thus ‘scale-free’, factors that influence the variance in a particular study can impact SMD and thereby compromise between-study comparisons. In addition, SMD is not robust to study outliers. Because outliers more strongly affect the variance than the mean, the presence of large outliers in a study can make SMD appear smaller than an analogous study without outliers. Alternative metrics that may better handle these issues require patient-level data, which was not available.

Where a study reported multiple outcomes, we selected a single one to use following an order of priority that favored statistical significance, as described in Methods. Our approach may therefore present a best-case scenario for timing effects. Alternative approaches that integrate *all* reported effects from a single study may be desirable but are challenging without patient-level data. Additionally, this meta-analysis did not consider binary outcomes, such as incidence of toxicity or survival, excluding ∼25 studies of chemotherapy timing in cancer. We collected data from these studies and provided it as a resource (Data file 1 in the Supplement).

## Conclusions

Despite many reports that attention to time-of-day can improve therapeutic outcomes, there is a critical need for both rigorous randomized controlled trials *and* analysis of real-world health data. Mechanistic insights from chronobiology will continue to drive hypotheses, but the burden of proof is clinical benefit. Published accounts of timing effects have tended to focus on *yes/no* significance. Future efforts to understand the range of likely effects should help clarify instances where consideration of time of day has the greatest medical potential.

## Data Availability

All data produced in this study are available upon request to the authors. However, all data produced can also be replicated by source code available on github and metadata available as a supplemental file.

## Supplement

![Fig 1 Supplement.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2021/10/26/2021.10.24.21265348/F5.medium.gif)

[Fig 1 Supplement.](http://medrxiv.org/content/early/2021/10/26/2021.10.24.21265348/F5)

Fig 1 Supplement. Selection of studies included in the meta-analysis (Methods).

![Fig 2 Supplement.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2021/10/26/2021.10.24.21265348/F6.medium.gif)

[Fig 2 Supplement.](http://medrxiv.org/content/early/2021/10/26/2021.10.24.21265348/F6)

Fig 2 Supplement. Influence of study features on timing effects
(**A**) Mixed-effects model pools the effect of each study design subgroup and compares between them. (**B**) Raw mean difference (RMD) for each distinct drug or drug combination that tested the effect of morning vs. evening dosing on nighttime systolic blood pressure. (**C**) Meta-regression of SMD onto drug half-life. *Point size*: study weight, ie., the contribution of each study to the estimated pooled effect. *Model coefficients*: R2 = percent of between-study variation explained by the model, I2 = residual heterogeneity, or the remaining variability between-studies not captured by half-life predictor, and p-value for difference between groups via Q-test. *Drug class abbreviations:* mAChRi: anticholinergic, A2-agonist: alpha 2 adrenergic receptor agonist, CORT: corticosteroid, GlucagonR-i: glucagon-like peptide-1 receptor agonist, VKA: vitamin K antagonist, SERM: selective estrogen receptor modulator; MRA: mineralocorticoid receptor antagonist.

## 78 Meta-analysis Studies

View this table:
[Table 1 Supplement.](http://medrxiv.org/content/early/2021/10/26/2021.10.24.21265348/T1)

Table 1 Supplement. 
All studies included in this meta-analysis.

## Article Information

### Data deposition

Data and code for reproducing the analyses in this study have been deposited in GitHub ([https://github.com/MarcDRuben/MetaAnalysis](https://github.com/MarcDRuben/MetaAnalysis)).

### Corresponding Authors

Marc D. Ruben PhD. Divisions of Human Genetics and Immunobiology, Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, USA (mruben1975{at}gmail.com).

John B. Hogenesch, PhD. Divisions of Human Genetics and Immunobiology, Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, USA (hogenesch{at}gmail.com).

### Author Contributions

Dr. Ruben had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

*Concept and design*: Ruben

*Acquisition, analysis, or interpretation of data*: All authors

*Drafting of the manuscript*: Ruben, Francey, Wu, Hughey

*Critical revision of the manuscript for important intellectual content*: All authors

*Statistical analysis*: Ruben, Hughey, Wu

*Obtained funding*: Hogenesch

Supervision: Hogenesch, Hughey

### Conflict of Interest Disclosures

None.

### Funding/Support

This work is supported by the National Institute of Neurological Disorders and Stroke (2R01NS054794 to JBH and Andrew Liu), the National Heart, Lung, and Blood Institute (R01HL138551 to Eric Bittman and JBH), and National Cancer Institute (1R01CA22748501A1 to Ron Anafi and JBH).

### Role of the Funder/Sponsor

The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

*   Received October 24, 2021.
*   Revision received October 24, 2021.
*   Accepted October 26, 2021.


*   © 2021, Posted by Cold Spring Harbor Laboratory

This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)

## References

1.  1.Rijo-Ferreira F, Takahashi JS. Genomics of circadian rhythms in health and disease. Genome Med. 2019;11(1):82.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/s13073-019-0704-0&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=31847894&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

2.  2.Allada R, Bass J. Circadian Mechanisms in Medicine. N Engl J Med. 2021;384(6):550–561.
    
    

3.  3.Long JE, Drayson MT, Taylor AE, Toellner KM, Lord JM, Phillips AC. Morning vaccination enhances antibody response over afternoon vaccination: A cluster-randomised trial. Vaccine. 2016;34(24):2679–2685.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.vaccine.2016.04.032&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=27129425&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

4.  4.de Bree LCJ, Mourits VP, Koeken VA, et al. Circadian rhythm influences induction of trained immunity by BCG vaccination. J Clin Invest. Published online July 21, 2020. doi:10.1172/JCI133934
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1172/JCI133934&link_type=DOI) 

5.  5.Bowles NP, Thosar SS, Herzig MX, Shea SA. Chronotherapy for Hypertension. Curr Hypertens Rep. 2018;20(11):97.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

6.  6.Smolensky MH, Hermida RC, Ayala DE, Tiseo R, Portaluppi F. Administration-time-dependent effects of blood pressure-lowering medications: basis for the chronotherapy of hypertension. Blood Press Monit. 2010;15(4):173–180.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/MBP.0b013e32833c7308&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20571367&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000279875000001&link_type=ISI) 

7.  7.Ruben MD, Smith DF, FitzGerald GA, Hogenesch JB. Dosing time matters. Science. 2019;365(6453):547–549.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6Mzoic2NpIjtzOjU6InJlc2lkIjtzOjEyOiIzNjUvNjQ1My81NDciO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMS8xMC8yNi8yMDIxLjEwLjI0LjIxMjY1MzQ4LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

8.  8.Lemmer B, Middeke M. Insufficient reply by Hermida et al. to the critical comments to the MAPEC and HYGIA studies. Chronobiol Int. Published online September 1, 2020:1.
    
    

9.  9.Kreutz R, Kjeldsen SE, Burnier M, Narkiewicz K, Oparil S, Mancia G. Blood pressure medication should not be routinely dosed at bedtime. We must disregard the data from the HYGIA project. J Hypertens. Published online August 17, 2020. doi:10.1097/HJH.0000000000002479
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/HJH.0000000000002479&link_type=DOI) 

10. 10.Crespo JJ, Domínguez-Sardiña M, Otero A, et al. Bedtime hypertension chronotherapy best reduces cardiovascular disease risk as corroborated by the Hygia Chronotherapy Trial. Rebuttal to European Society of Hypertension officials. Chronobiology International. 2020;37(5):771–780. doi:10.1080/07420528.2020.1781351
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1080/07420528.2020.1781351&link_type=DOI) 

11. 11.Bautista LE, Vera LM. Antihypertensive effects of aspirin: what is the evidence? Curr Hypertens Rep. 2010;12(4):282–289.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s11906-010-0115-5&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20524092&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

12. 12.Turgeon RD, Althouse AD, Cohen JB, et al. Lowering Nighttime Blood Pressure With Bedtime Dosing of Antihypertensive Medications: Controversies in Hypertension - Con Side of the Argument. Hypertension. 2021;78(3):871–878.
    
    

13. 13.Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/0197-2456(95)00134-4&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=8721797&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=A1996UA39800001&link_type=ISI) 

14. 14.Cohen J. Statistical Power Analysis for the Behavioral Sciences. Published online 2013. doi:10.4324/9780203771587
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.4324/9780203771587&link_type=DOI) 

15. 15.Hedges LV, Olkin I. Statistical Methods for Meta-Analysis.; 1985:1–14.
    
    

16. 16.Lüdecke D. Esc: Effect Size Computation for Meta Analysis (Version 0.4. 1).; 2018. doi:10.5281/zenodo.1249218
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.5281/zenodo.1249218&link_type=DOI) 

17. 17.Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis.; 2009.
    
    

18. 18.Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons; 2019.
    
    

19. 19.Shi J, Luo D, Weng H, et al. Optimally estimating the sample standard deviation from the five-number summary. Res Synth Methods. 2020;11(5):641–654.
    
    

20. 20.Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785–1805.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1177/0962280216669183&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

21. 21.DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. Published online 1986. [https://www.sciencedirect.com/science/article/pii/0197245686900462](https://www.sciencedirect.com/science/article/pii/0197245686900462)
    
    

22. 22.Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153–160.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6ODoiZWJtZW50YWwiO3M6NToicmVzaWQiO3M6ODoiMjIvNC8xNTMiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMS8xMC8yNi8yMDIxLjEwLjI0LjIxMjY1MzQ4LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

23. 23.Harrer M, Cuijpers P, Furukawa T, Ebert DD. Dmetar: Companion R Package For The Guide “Doing Meta-Analysis in R.”; 2019. [http://dmetar.protectlab.org/](http://dmetar.protectlab.org/)
    
    

24. 24.Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2017;46(D1):D1074–D1082.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/nar/gkx1037&link_type=DOI) 

25. 25.Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjEyOiIzMTUvNzEwOS82MjkiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMS8xMC8yNi8yMDIxLjEwLjI0LjIxMjY1MzQ4LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

26. 26.Sterne JAC, Sutton AJ, Ioannidis JPA, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.
    
    [FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiRlVMTCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjE3OiIzNDMvanVsMjJfMS9kNDAwMiI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIxLzEwLzI2LzIwMjEuMTAuMjQuMjEyNjUzNDguYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

27. 27.Harrer, M., Cuijpers, P., Furukawa, T.A, & Ebert, D. D. Doing Meta-Analysis in R: A Hands-on Guide. Published 2019. Accessed 2021. [https://bookdown.org/MathiasHarrer/Doing\_Meta\_Analysis\_in\_R/](https://bookdown.org/MathiasHarrer/Doing\_Meta_Analysis_in_R/)
    
    

28. 28.Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560.
    
    [FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiRlVMTCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjEyOiIzMjcvNzQxNC81NTciO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMS8xMC8yNi8yMDIxLjEwLjI0LjIxMjY1MzQ4LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

29. 29.IntHout J, Ioannidis JPA, Rovers MM, Goeman JJ. Plea for routinely presenting prediction intervals in meta-analysis. BMJ Open. 2016;6(7):e010247. doi:10.1136/bmjopen-2015-010247
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NzoiYm1qb3BlbiI7czo1OiJyZXNpZCI7czoxMToiNi83L2UwMTAyNDciO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMS8xMC8yNi8yMDIxLjEwLjI0LjIxMjY1MzQ4LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

30. 30.Belsley DA, Kuh E, Welsch RE. Regression Diagnostics: Identifying Influential Data and Sources of Collinearity. John Wiley & Sons. pp. 11–16. ISBN 0-471-05856-4; 1980.
    
    

31. 31.Borenstein M, Higgins JPT. Meta-analysis and subgroups. Prev Sci. 2013;14(2):134–143.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=23479191&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

32. 32.Simes RJ. Publication bias: the case for an international registry of clinical trials. J Clin Oncol. 1986;4(10):1529–1541.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiamNvIjtzOjU6InJlc2lkIjtzOjk6IjQvMTAvMTUyOSI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIxLzEwLzI2LzIwMjEuMTAuMjQuMjEyNjUzNDguYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

33. 33.Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K. Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst Rev. 2009;(1):MR000006.
    
    

34. 34.Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000;53(11):1119–1129.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0895-4356(00)00242-0&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=11106885&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000165471900006&link_type=ISI) 

35. 35.Rothstein HR, Sutton AJ, Borenstein M. Publication Bias in Meta-Analysis: Prevention, Assessment and Adjustments. John Wiley & Sons; 2006.
    
    

36. 36.Cummings P. Arguments for and against standardized mean differences (effect sizes). Arch Pediatr Adolesc Med. 2011;165(7):592–596.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/archpediatrics.2011.97&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21727271&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

37. 37.Greenland S, Schlesselman JJ, Criqui MH. The fallacy of employing standardized regression coefficients and correlations as measures of effect. Am J Epidemiol. 1986;123(2):203–208.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=3946370&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=A1986AYS5700001&link_type=ISI) 

38. 38.Bendzala M, Kruzliak P, Gaspar L, et al. Prognostic significance of dipping in older hypertensive patients. Blood Pressure. 2015;24(2):103–110. doi:10.3109/08037051.2014.992198
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3109/08037051.2014.992198&link_type=DOI) 

39. 39.Mancia G, Parati G. The role of blood pressure variability in end-organ damage. J Hypertens Suppl. 2003;21(6):S17–S23.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/00004872-200307006-00004&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=14513947&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

40. 40.Brotman DJ, Davidson MB, Boumitri M, Vidt DG. Impaired diurnal blood pressure variation and all-cause mortality. Am J Hypertens. 2008;21(1):92–97.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/ajh.2007.7&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=18091750&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

41. 41.Scheer FAJL, Michelson AD, Frelinger AL 3rd., et al. The human endogenous circadian system causes greatest platelet activation during the biological morning independent of behaviors. PLoS One. 2011;6(9):e24549.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0024549&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21931750&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

42. 42.Tofler GH, Brezinski D, Schafer AI, et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med. 1987;316(24):1514–1518.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJM198706113162405&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=3587281&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=A1987H640800005&link_type=ISI) 

43. 43.Degaute JP, van de Borne P, Linkowski P, Van Cauter E. Quantitative analysis of the 24-hour blood pressure and heart rate patterns in young men. Hypertension. 1991;18(2):199–210.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1161/01.HYP.18.2.199&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=1885228&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

44. 44.Ridker PM, Manson JE, Buring JE, Muller JE, Hennekens CH. Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians. Circulation. 1990;82(3):897–902.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTQ6ImNpcmN1bGF0aW9uYWhhIjtzOjU6InJlc2lkIjtzOjg6IjgyLzMvODk3IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjEvMTAvMjYvMjAyMS4xMC4yNC4yMTI2NTM0OC5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

45. 45.Innominato PF, Ballesta A, Huang Q, et al. Sex-dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial. Cancer Medicine. Published online 2020. doi:10.1002/cam4.3056
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/cam4.3056&link_type=DOI) 

46. 46.Phillips AC, Gallagher S, Carroll D, Drayson M. Preliminary evidence that morning vaccination is associated with an enhanced antibody response in men. Psychophysiology. 2008;45(4):663–666. doi:10.1111/j.1469-8986.2008.00662.x
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/j.1469-8986.2008.00662.x&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=18346041&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

47. 47.Byrne RA, Colleran R. Aspirin for secondary prevention of cardiovascular disease. Lancet. 2020;395(10235):1462–1463.
    
    

48. 48.Leucht S, Helfer B, Gartlehner G, Davis JM. How effective are common medications: a perspective based on meta-analyses of major drugs. BMC Med. 2015;13:253.
    
    

49. 49.Ricciotti E, FitzGerald GA. Aspirin in the Prevention of Cardiovascular Disease and Cancer. Annu Rev Med. 2021;72:473–495.
    
    

50. 50.Patrono C. Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back. Trends Pharmacol Sci. 1989;10(11):453–458.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0165-6147(89)80010-0&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=2514478&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=A1989CA35600009&link_type=ISI) 

51. 51.Di Minno G, Silver MJ, Murphy S. Monitoring the entry of new platelets into the circulation after ingestion of aspirin. Blood. 1983;61(6):1081–1085.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTI6ImJsb29kam91cm5hbCI7czo1OiJyZXNpZCI7czo5OiI2MS82LzEwODEiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMS8xMC8yNi8yMDIxLjEwLjI0LjIxMjY1MzQ4LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

52. 52.Patrono C, Ciabattoni G, Patrignani P, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 1985;72(6):1177–1184.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTQ6ImNpcmN1bGF0aW9uYWhhIjtzOjU6InJlc2lkIjtzOjk6IjcyLzYvMTE3NyI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIxLzEwLzI2LzIwMjEuMTAuMjQuMjEyNjUzNDguYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

53. 53.Grove EL, Hvas AM, Mortensen SB, Larsen SB, Kristensen SD. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost. 2011;9(1):185–191.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/j.1538-7836.2010.04115.x&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20955349&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

54. 54.Würtz M, Hvas A-M, Jensen LO, et al. 24-hour antiplatelet effect of aspirin in patients with previous definite stent thrombosis. Int J Cardiol. 2014;175(2):274–279.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.ijcard.2014.05.013&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=24861258&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

55. 55.Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation. 1989;79(4):733–743.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTQ6ImNpcmN1bGF0aW9uYWhhIjtzOjU6InJlc2lkIjtzOjg6Ijc5LzQvNzMzIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjEvMTAvMjYvMjAyMS4xMC4yNC4yMTI2NTM0OC5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

56. 56.Bonten TN, Snoep JD, Assendelft WJJ, et al. Time-dependent effects of aspirin on blood pressure and morning platelet reactivity: a randomized cross-over trial. Hypertension. 2015;65(4):743–750.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1161/HYPERTENSIONAHA.114.04980&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25691622&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

57. 57.van Diemen JJK, Madsen MC, Vrancken P, et al. Evening aspirin intake results in higher levels of platelet inhibition and a reduction in reticulated platelets - a window of opportunity for patients with cardiovascular disease? Platelets. 2021;32(6):821–827.
    
    

58. 58.Hendel J, Hendel L, Aggestrup S. Morning or evening dosage of omeprazole for gastro-oesophageal reflux disease? Aliment Pharmacol Ther. 1995;9(6):693–697.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=8824658&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

59. 59.Chen L, Yang G, Zhang J, et al. Time-Dependent Hypotensive Effect of Aspirin in Mice. Arterioscler Thromb Vasc Biol. 2018;38(12):2819–2826.
    
    

60. 60.Krasińska B, Paluszkiewicz L, Miciak-Ławicka E, et al. The impact of acetylsalicylic acid dosed at bedtime on circadian rhythms of blood pressure in the high-risk group of cardiovascular patients-a randomized, controlled trial. Eur J Clin Pharmacol. Published online September 21, 2020. doi:10.1007/s00228-020-02997-8
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s00228-020-02997-8&link_type=DOI) 

61. 61.Hermida RC, Crespo JJ, Domínguez-Sardiña M, et al. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. European Heart Journal. Published online 2019. doi:10.1093/eurheartj/ehz754
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/eurheartj/ehz754&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=31641769&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

62. 62.Zappe DH, Crikelair N, Kandra A, Palatini P. Time of administration important? Morning versus evening dosing of valsartan. J Hypertens. 2015;33(2):385–392.
    
    

63. 63.Ruben MD, Francey LJ, Guo Y, et al. A large-scale study reveals 24-h operational rhythms in hospital treatment. Proc Natl Acad Sci U S A. 2019;116(42):20953–20958.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoicG5hcyI7czo1OiJyZXNpZCI7czoxMjoiMTE2LzQyLzIwOTUzIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjEvMTAvMjYvMjAyMS4xMC4yNC4yMTI2NTM0OC5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

64. 64.Rahman M, Greene T, Phillips RA, et al. A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease. Hypertension. 2013;61(1):82–88.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1161/HYPERTENSIONAHA.112.200477&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=23172931&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

65. 65.Tiwari V, Chaudhary AR, Dasgupta S, et al. Effect of chronotherapy of antihypertensives in chronic kidney disease: A randomized control trial. Published online 2020. [https://www.indianjnephrol.org/preprintarticle.asp?id=300526](https://www.indianjnephrol.org/preprintarticle.asp?id=300526)
    
    

66. 66.Wang C, Zhang J, Liu X, et al. Effect of valsartan with bedtime dosing on chronic kidney disease patients with nondipping blood pressure pattern. J Clin Hypertens. 2013;15(1):48–54.
    
    

67. 67.Ayala DE, Ucieda R, Hermida RC. Chronotherapy with low-dose aspirin for prevention of complications in pregnancy. Chronobiol Int. 2013;30(1-2):260–279.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3109/07420528.2012.717455&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=23004922&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

68. 68.Zeng J, Jia M, Ran H, et al. Fixed-combination of amlodipine and diuretic chronotherapy in the treatment of essential hypertension: improved blood pressure control with bedtime dosing-a multicenter, open-label randomized study. Hypertens Res. 2011;34(6):767–772.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/hr.2011.36&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21471971&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

69. 69.Kasiakogias A, Tsioufis C, Thomopoulos C, et al. Evening versus morning dosing of antihypertensive drugs in hypertensive patients with sleep apnoea. Journal of Hypertension. 2015;33(2):393–400. doi:10.1097/hjh.0000000000000371
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/HJH.0000000000000371&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25318654&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

70. 70.Asmar R, Gosse P, Queré S, Achouba A. Efficacy of morning and evening dosing of amlodipine/valsartan combination in hypertensive patients uncontrolled by 5 mg of amlodipine. Blood Press Monit. 2011;16(2):80–86.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21372694&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

71. 71.Hermida RC, Ayala DE, Fontao MJ, Mojón A, Fernández JR. Chronotherapy with valsartan/amlodipine fixed combination: improved blood pressure control of essential hypertension with bedtime dosing. Chronobiol Int. 2010;27(6):1287–1303.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20653455&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

72. 72.Hoshino A, Nakamura T, Matsubara H. The bedtime administration ameliorates blood pressure variability and reduces urinary albumin excretion in amlodipine-olmesartan combination therapy. Clin Exp Hypertens. 2010;32(7):416–422.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20828223&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

73. 73.Hermida RC, Ayala DE, Fontao MJ, Mojón A, Alonso I, Fernández JR. Administration-time-dependent effects of spirapril on ambulatory blood pressure in uncomplicated essential hypertension. Chronobiol Int. 2010;27(3):560–574.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3109/07420528.2010.485411&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20524801&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

74. 74.Hermida RC, Ayala DE. Chronotherapy with the angiotensin-converting enzyme inhibitor ramipril in essential hypertension: improved blood pressure control with bedtime dosing. Hypertension. 2009;54(1):40–46.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1161/HYPERTENSIONAHA.109.130203&link_type=DOI) 

75. 75.Hermida RC, Ayala DE, Mojón A, Alonso I, Fernández JR. Reduction of morning blood pressure surge after treatment with nifedipine GITS at bedtime, but not upon awakening, in essential hypertension. Blood Press Monit. 2009;14(4):152–159.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/MBP.0b013e32832e0d80&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=19543080&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000268690600003&link_type=ISI) 

76. 76.Hermida RC, Ayala DE, Chayan L, Mojon A, Fernandez JR. Administration-time-dependent effects of olmesartan on the ambulatory blood pressure of essential hypertension patients. Chronobiol Int. 2009;26(1):61–79.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1080/07420520802548135&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=19142758&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

77. 77.Mori H, on behalf of the COMPATIBLE Study Group, Yamamoto H, et al. Comparison of effects of angiotensin II receptor blocker on morning home blood pressure and cardiorenal protection between morning administration and evening administration in hypertensive patients: the COMPATIBLE study. Hypertension Research. 2013;36(3):202–207. doi:10.1038/hr.2012.142
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/hr.2012.142&link_type=DOI) 

78. 78.Ushijima K, Nakashima H, Shiga T, et al. Different chronotherapeutic effects of valsartan and olmesartan in non-dipper hypertensive patients during valsartan treatment at morning. J Pharmacol Sci. 2015;127(1):62–68.
    
    

79. 79.Hermida RC, Ayala DE, Mojón A, Fernández JR. Ambulatory blood pressure control with bedtime aspirin administration in subjects with prehypertension. Am J Hypertens. 2009;22(8):896–903.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/ajh.2009.83&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=19407805&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

80. 80.Hermida RC, Ayala DE, Fernández JR, Calvo C. Comparison of the efficacy of morning versus evening administration of telmisartan in essential hypertension. Hypertension. 2007;50(4):715–722.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1161/HYPERTENSIONAHA.107.094235&link_type=DOI) 

81. 81.Hermida RC, Calvo C, Ayala DE, et al. Treatment of non-dipper hypertension with bedtime administration of valsartan. J Hypertens. 2005;23(10):1913–1922.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/01.hjh.0000182522.21569.c5&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=16148616&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000232383400024&link_type=ISI) 

82. 82.Hermida RC, Ayala DE, Calvo C, et al. Differing administration time-dependent effects of aspirin on blood pressure in dipper and non-dipper hypertensives. Hypertension. 2005;46(4):1060–1068.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1161/01.HYP.0000172623.36098.4e&link_type=DOI) 

83. 83.Qiu Y-G, Chen J-Z, Zhu J-H, Yao X-Y. Differential effects of morning or evening dosing of amlodipine on circadian blood pressure and heart rate. Cardiovasc Drugs Ther. 2003;17(4):335–341.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1023/A:1027347723347&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=14618095&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

84. 84.Serinel Y, Yee BJ, Grunstein RR, et al. Chronotherapy for hypertension in obstructive sleep apnoea (CHOSA): a randomised, double-blind, placebo-controlled crossover trial. Thorax. 2017;72(6):550–558.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6OToidGhvcmF4am5sIjtzOjU6InJlc2lkIjtzOjg6IjcyLzYvNTUwIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjEvMTAvMjYvMjAyMS4xMC4yNC4yMTI2NTM0OC5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

85. 85.Hjortkjær HØ, Jensen T, Kofoed KF, et al. Nocturnal antihypertensive treatment in patients with type 1 diabetes with autonomic neuropathy and non-dipping: a randomised, placebo-controlled, double-blind cross-over trial. BMJ Open. 2016;6(12):e012307.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NzoiYm1qb3BlbiI7czo1OiJyZXNpZCI7czoxMjoiNi8xMi9lMDEyMzA3IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjEvMTAvMjYvMjAyMS4xMC4yNC4yMTI2NTM0OC5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

86. 86.Kitahara Y, Saito F, Akao M, et al. Effect of morning and bedtime dosing with cilnidipine on blood pressure, heart rate, and sympathetic nervous activity in essential hypertensive patients. J Cardiovasc Pharmacol. 2004;43(1):68–73.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=14668570&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

87. 87.Hermida RC, Ayala DE, Mojón A, et al. Comparison of the effects on ambulatory blood pressure of awakening versus bedtime administration of torasemide in essential hypertension. Chronobiol Int. 2008;25(6):950–970.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1080/07420520802544589&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=19005898&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

88. 88.Hermida RC, Calvo C, Ayala DE, et al. Administration time-dependent effects of valsartan on ambulatory blood pressure in elderly hypertensive subjects. Chronobiol Int. 2005;22(4):755–776.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1080/07420520500180488&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=16147905&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

89. 89.Kohno I, Ijiri H, Takusagawa M, et al. Effect of imidapril in dipper and nondipper hypertensive patients: comparison between morning and evening administration. Chronobiol Int. 2000;17(2):209–219.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1081/CBI-100101044&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=10757465&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

90. 90.Farah R, Makhoul N, Arraf Z, Khamisy-Farah R. Switching therapy to bedtime for uncontrolled hypertension with a nondipping pattern: a prospective randomized-controlled study. Blood Press Monit. 2013;18(4):227–231.
    
    

91. 91.Rossen NB, Knudsen ST, Fleischer J, et al. Targeting nocturnal hypertension in type 2 diabetes mellitus. Hypertension. 2014;64(5):1080–1087.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1161/HYPERTENSIONAHA.114.03958&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25259747&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

92. 92.Fujiwara T, Hoshide S, Yano Y, Kanegae H, Kario K. Comparison of morning vs bedtime administration of the combination of valsartan/amlodipine on nocturnal brachial and central blood pressure in patients with hypertension. The Journal of Clinical Hypertension. 2017;19(12):1319–1326. doi:10.1111/jch.13128
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/jch.13128&link_type=DOI) 

93. 93.Huangfu W, Duan P, Xiang D, Gao R. Administration time-dependent effects of combination therapy on ambulatory blood pressure in hypertensive subjects. Int J Clin Exp Med. 2015;8(10):19156–19161.
    
    

94. 94.Kario K, Hoshide S, Uchiyama K, et al. Dose Timing of an Angiotensin II Receptor Blocker/Calcium Channel Blocker Combination in Hypertensive Patients With Paroxysmal Atrial Fibrillation. J Clin Hypertens. 2016;18(10):1036–1044.
    
    

95. 95.Dimitrov Y, Baguet J-P, Hottelart C, et al. Is there a BP benefit of changing the time of aspirin administration in treated hypertensive patients? Eur J Prev Cardiol. 2012;19(4):706–711.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1177/1741826711418165&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21810842&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

96. 96.Suomela I, Varis J, Kantola I. The antihypertensive effect of ASA lasts less than 24 hours? World J Cardiovasc Dis. 2015;05(03):62–70.
    
    

97. 97.Khodadoustan S, Nasri Ashrafi I, Vanaja Satheesh K, Kumar C, Hs S S C. Evaluation of the effect of time dependent dosing on pharmacokinetic and pharmacodynamics of amlodipine in normotensive and hypertensive human subjects. Clin Exp Hypertens. 2017;39(6):520–526.
    
    

98. 98.Krasińska B, Paluszkiewicz L, Miciak-Lawicka E, et al. The effect of acetylsalicylic acid dosed at bedtime on the anti-aggregation effect in patients with coronary heart disease and arterial hypertension: A randomized, controlled trial. Cardiol J. Published online 2018. [https://journals.viamedica.pl/cardiology\_journal/article/view/59887](https://journals.viamedica.pl/cardiology_journal/article/view/59887)
    
    

99. 99.Racca C, van Diemen JJK, Fuijkschot WW, et al. Aspirin intake in the morning is associated with suboptimal platelet inhibition, as measured by serum Thromboxane B2, during infarct-prone early-morning hours. Platelets. Published online October 22, 2018:1-7.
    
    

100.100.Brunner-Ziegler S, Jilma B, Schörgenhofer C, et al. Comparison between the impact of morning and evening doses of rivaroxaban on the circadian endogenous coagulation rhythm in healthy subjects. J Thromb Haemost. 2016;14(2):316–323.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/jth.13213&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

101.101.Garrison SR, Green L, Kolber MR, et al. The Effect of Warfarin Administration Time on Anticoagulation Stability (INRange): A Pragmatic Randomized Controlled Trial. Ann Fam Med. 2020;18(1):42–49.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6ODoiYW5uYWxzZm0iO3M6NToicmVzaWQiO3M6NzoiMTgvMS80MiI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIxLzEwLzI2LzIwMjEuMTAuMjQuMjEyNjUzNDguYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

102.102.Ando H, Otoda T, Ookami H, et al. Dosing time-dependent effect of raloxifene on plasma plasminogen activator inhibitor-1 concentrations in post-menopausal women with osteoporosis. Clin Exp Pharmacol Physiol. 2013;40(3):227–232.
    
    

103.103.Chipchura DA, Freyberg Z, Edwards C, Leckband SG, McCarthy MJ. Does the Time of Drug Administration Alter the Metabolic Risk of Aripiprazole? Front Psychiatry. 2018;9:494.
    
    

104.104.Ozaydin M, Dede O, Dogan A, et al. Effects of morning versus evening intake of atorvastatin on major cardiac event and restenosis rates in patients undergoing first elective percutaneous coronary intervention. Am J Cardiol. 2006;97(1):44–47.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.amjcard.2005.07.107&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=16377282&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000234587200011&link_type=ISI) 

105.105.Tharavanij T, Wongtanakarn S, Lerdvuthisopon N, Teeraaunkul S, Youngsriphithak P, Sritipsukho P. Lipid lowering efficacy between morning and evening simvastatin treatment: a randomized double-blind study. J Med Assoc Thai. 2010;93 Suppl 7:S109–S113.
    
    

106.106.Lafeber M, Grobbee DE, Schrover IM, et al. Comparison of a morning polypill, evening polypill and individual pills on LDL-cholesterol, ambulatory blood pressure and adherence in high-risk patients; a randomized crossover trial. International Journal of Cardiology. 2015;181:193–199. doi:10.1016/j.ijcard.2014.11.176
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.ijcard.2014.11.176&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25528311&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

107.107.Wallace A, Chinn D, Rubin G. Taking simvastatin in the morning compared with in the evening: randomised controlled trial. BMJ. 2003;327(7418):788.
    
    [FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiRlVMTCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjEyOiIzMjcvNzQxOC83ODgiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMS8xMC8yNi8yMDIxLjEwLjI0LjIxMjY1MzQ4LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

108.108.Lund TM, Torsvik H, Falch D, Christophersen B, Skårdal R, Gullestad L. Effect of morning versus evening intake of simvastatin on the serum cholesterol level in patients with coronary artery disease. Am J Cardiol. 2002;90(7):784–786.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0002-9149(02)02614-0&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=12356401&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

109.109.Kim S-H, Kim M-K, Seo H-S, et al. Efficacy and safety of morning versus evening dose of controlled-release simvastatin tablets in patients with hyperlipidemia: a randomized, double-blind, multicenter phase III trial. Clin Ther. 2013;35(9):1350–1360.e1.
    
    

110.110.Yoon HS, Kim SH, Kim JK, et al. Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia. Ann Pharmacother. 2011;45(7-8):841–849.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1345/aph.1P511&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21693699&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

111.111.Plakogiannis R, Cohen H, Taft D. Effects of morning versus evening administration of atorvastatin in patients with hyperlipidemia. Am J Health Syst Pharm. 2005;62(23):2491–2494.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoiYWpocCI7czo1OiJyZXNpZCI7czoxMDoiNjIvMjMvMjQ5MSI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIxLzEwLzI2LzIwMjEuMTAuMjQuMjEyNjUzNDguYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

112.112.Poulter NR, Savopoulos C, Anjum A, et al. Randomized Crossover Trial of the Impact of Morning or Evening Dosing of Antihypertensive Agents on 24-Hour Ambulatory Blood Pressure. Hypertension. 2018;72(4):870–873. doi:10.1161/hypertensionaha.118.11101
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1161/hypertensionaha.118.11101&link_type=DOI) 

113.113.Bach-Huynh T-G, Nayak B, Loh J, Soldin S, Jonklaas J. Timing of Levothyroxine Administration Affects Serum Thyrotropin Concentration. The Journal of Clinical Endocrinology & Metabolism. 2009;94(10):3905–3912. doi:10.1210/jc.2009-0860
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1210/jc.2009-0860&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=19584184&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000270526500037&link_type=ISI) 

114.114.Bolk N, Visser TJ, Nijman J, Jongste IJ, Tijssen JGP, Berghout A. Effects of evening vs morning levothyroxine intake: a randomized double-blind crossover trial. Arch Intern Med. 2010;170(22):1996–2003.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/archinternmed.2010.436&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21149757&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000285270800008&link_type=ISI) 

115.115.Elliott DP. Effect of Levothyroxine Administration Time on Serum TSH in Elderly Patients. Annals of Pharmacotherapy. 2001;35(5):529–532. doi:10.1345/aph.10286
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1345/aph.10286&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=11346056&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000168433300001&link_type=ISI) 

116.116.Packard A, Arciniegas AA, Smotherman C. Effectiveness of preventive onabotulinumtoxin A injections for migraine headaches is dependent on the circadian time of administration. Chronobiol Int. Published online December 13, 2020:1-8.
    
    

117.117.Buttgereit F, Doering G, Schaeffler A, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet. 2008;371(9608):205–214.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(08)60132-4&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=18207016&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000252471900024&link_type=ISI) 

118.118.Calverley PMA, Lee A, Towse L, van Noord J, Witek TJ, Kelsen S. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax. 2003;58(10):855–860.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6OToidGhvcmF4am5sIjtzOjU6InJlc2lkIjtzOjk6IjU4LzEwLzg1NSI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIxLzEwLzI2LzIwMjEuMTAuMjQuMjEyNjUzNDguYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

119.119.Zetterström O, Dahl R, Lindqvist A, Olsson P. Comparable morning versus evening administration of once-daily mometasone furoate dry powder inhaler. Respir Med. 2008;102(10):1406–1411.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=18640826&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

120.120.Kempsford RD, Bal J, Baines A, Renaux J, Ravindranath R, Thomas PS. The efficacy of fluticasone furoate administered in the morning or evening is comparable in patients with persistent asthma. Respir Med. 2016;112:18–24.
    
    

121.121.Kempsford RD, Oliver A, Bal J, Tombs L, Quinn D. The efficacy of once-daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respir Med. 2013;107(12):1873–1880.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.rmed.2013.07.002&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=24200619&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

122.122.Ren S-S, Xu L-L, Wang P, et al. Circadian Rhythms Have Effects on Surgical Outcomes of Liver Transplantation for Patients With Hepatocellular Carcinoma: A Retrospective Analysis of 147 Cases in a Single Center. Transplant Proc. 2019;51(6):1913–1919.
    
    

123.123.Montaigne D, Marechal X, Modine T, et al. Daytime variation of perioperative myocardial injury in cardiac surgery and its prevention by Rev-Erbα antagonism: a single-centre propensity-matched cohort study and a randomised study. Lancet. Published online October 26, 2017. doi:10.1016/S0140-6736(17)32132-3
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(17)32132-3&link_type=DOI) 

124.124.Ahrén B, Leguizamo Dimas A, Miossec P, Saubadu S, Aronson R. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care. 2013;36(9):2543–2550.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NzoiZGlhY2FyZSI7czo1OiJyZXNpZCI7czo5OiIzNi85LzI1NDMiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMS8xMC8yNi8yMDIxLjEwLjI0LjIxMjY1MzQ4LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

125.125.Haye R, Høye K, Berg O, Frønes S, Odegård T. Morning versus evening dosing of desloratadine in seasonal allergic rhinitis: a randomized controlled study [[ISRCTN23032971](http://medrxiv.org/external-ref?link_type=ISRCTN&access_num=ISRCTN23032971)]. Clin Mol Allergy. 2005;3(1):3.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=15686600&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

126.126.Patti F, RELIEF Study Group, Zimatore GB, et al. Administration of subcutaneous interferon beta 1a in the evening: data from RELIEF study. Journal of Neurology. 2020;267(6):1812–1823. doi:10.1007/s00415-020-09771-x
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s00415-020-09771-x&link_type=DOI) 

127.127.Cheeseman JF, Merry AF, Pawley MDM, de Souza RL, Warman GR. The effect of time of day on the duration of neuromuscular blockade elicited by rocuronium. Anaesthesia. 2007;62(11):1114–1120.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=17924891&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 

128.128.Lucidi P, Cioli P, Candeloro P, Andreoli AM. Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes. Diabetes. Published online 2015. [https://care.diabetesjournals.org/content/38/3/503.short](https://care.diabetesjournals.org/content/38/3/503.short)
    
    

129.129.Garg SK, Gottlieb PA, Hisatomi ME, et al. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res Clin Pract. 2004;66(1):49–56.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.diabres.2004.02.008&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=15364161&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F10%2F26%2F2021.10.24.21265348.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000224337400007&link_type=ISI) 

130.130.Newcorn JH, Stein MA, Childress AC, et al. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration. J Am Acad Child Adolesc Psychiatry. 2013;52(9):921–930.

 [1]: /embed/graphic-1.gif
 [2]: /embed/graphic-2.gif
 [3]: /embed/graphic-3.gif
 [4]: F1/embed/inline-graphic-1.gif